Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

NCT04039503 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04039503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04039503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2019
Completion date
January 13, 2021
Enrollment
475 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes